GLP1R and Stroke: Kaplan-Meier analysis (Fig 3) confirmed these findings, with GLP-1 RAs significantly lowering the risk of primary composite cardiovascular events (P < 0.001), SHF (P < 0.001), and stroke (P = 0.035), while differences in mortality (P = 0.13) and acute MI (P = 0.10) remained non-significant during the 3-year follow-up.